Israel Health News API

{
    "totalArticles": 13818,
    "articles": [
        {
            "id": "7187d561056568c59a4af15d11df2f34",
            "title": "Researchers make 'surprising' discovery while studying prostate tumors: 'This issue deserves really serious attention'",
            "description": "Researchers are calling for broader studies.",
            "content": "A new study has uncovered a troubling potential link between microplastics and cancerous prostate tumors. While the study doesn't prove causation, it raises questions about the effects microplastics may have on the development of certain cancers.\nWha... [2591 chars]",
            "url": "https://www.yahoo.com/news/articles/researchers-surprising-discovery-while-studying-000000812.html",
            "image": "https://s.yimg.com/ny/api/res/1.2/l4L1Y1NMh7TuU7khkmQ8kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/the_cool_down_737/30b47c588c22b7954996a832efb7f99d",
            "publishedAt": "2026-03-03T00:00:00Z",
            "lang": "en",
            "source": {
                "id": "99e8a2cb4638bb798cf9167e5af5b83b",
                "name": "Yahoo",
                "url": "https://www.yahoo.com"
            }
        },
        {
            "id": "443c4e6138d3b0db7a58a0070818bace",
            "title": "1s and Healthy Lifestyle Help Lower Cardiovascular Risk",
            "description": "A recent study found that combing GLP-1 drugs with healthy lifestyle habits may help reduce cardiovascular risk in people with diabetes.",
            "content": "A recent study found that people with type 2 diabetes who used GLP-1 receptor agonists (GLP-1 RAs) in combination with healthy lifestyle habits had a reduced risk of major adverse cardiovascular events.\nThe findings show that GLP-1 RAs, when combined... [4578 chars]",
            "url": "https://www.healthline.com/health-news/glp-1-drugs-healthy-lifestyle-reduces-cardiovascular-risk-diabetes",
            "image": "https://media.post.rvohealth.io/wp-content/uploads/2026/03/GLP-1-lifestyle-GettyImages-2248287256-Facebook.jpg",
            "publishedAt": "2026-03-02T18:00:00Z",
            "lang": "en",
            "source": {
                "id": "401c985ddf345bff6f1916c516fcc1d2",
                "name": "Healthline",
                "url": "https://www.healthline.com"
            }
        },
        {
            "id": "4e6afb558daf01362b626f127c346465",
            "title": "Half the participants from placebo arm of HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies",
            "description": "In the second phase of the RIO HIV cure trial, participants originally given a placebo were offered the experimental therapy, the Conference on Retroviruses and Opportunistic Infections (CROI 2026) heard last week. More than half of them responded with a prolonged period of low or undetectable viral load and were able to put off resuming their HIV therapy for more than 20 weeks. Two are still off antiretroviral therapy (ART) after more than a year.\n[GLOSSARY]",
            "content": "In the second phase of the RIO HIV cure trial, participants originally given a placebo were offered the experimental therapy, the Conference on Retroviruses and Opportunistic Infections (CROI 2026) heard last week. More than half of them responded wi... [3670 chars]",
            "url": "https://www.aidsmap.com/news/mar-2026/half-participants-placebo-arm-hiv-cure-trial-have-prolonged-viral-load-remission-when",
            "image": "https://www.aidsmap.com/sites/default/files/styles/aidsmap_social_default/public/2026-03/aidsmap%202000x1300-croi-john-frater.png?itok=QEE1rLXk",
            "publishedAt": "2026-03-02T17:53:46Z",
            "lang": "en",
            "source": {
                "id": "675d07a0f827bffe57bc261462fba8c6",
                "name": "Aidsmap",
                "url": "https://www.aidsmap.com"
            }
        }
    ]
}